Satoris, a Redwood City, Calif. company that makes bloodstream-based diagnostic tests for Alzheimer’s disease, says it has raised $1.12 million toward an anticipated $1.5 million bridge round, which will be used to commercialize its lead product, reports VentureWire.
The plan is to market the tests to researchers and pharmaceutical companies as a precise way to track the progression of the disease. Eventually, the company says it will follow up with a clinical test — contingent on its ability to raise another, larger round of capital.
Brain Trust Acclerator Fund and Life Science Angels joined several private investors to provide the recent round. The company last raised funds in December 2007, bringing in a little over $5 million in a second round of funding. It has raised $7.5 million to date.
VentureBeatVentureBeat's mission is to be a digital town square for technical decision-makers to gain knowledge about transformative technology and transact. Our site delivers essential information on data technologies and strategies to guide you as you lead your organizations. We invite you to become a member of our community, to access:
- up-to-date information on the subjects of interest to you
- our newsletters
- gated thought-leader content and discounted access to our prized events, such as Transform 2021: Learn More
- networking features, and more